Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A., Schmidt, H. H., . . . Coelho, T. (2021). Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. The lancet, 20(1), . https://doi.org/10.1016/S1474-4422(20)30368-9
Chicago-Zitierstil (17. Ausg.)Adams, David, et al. "Long-term Safety and Efficacy of Patisiran for Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: 12-month Results of an Open-label Extension Study." The Lancet 20, no. 1 (2021). https://doi.org/10.1016/S1474-4422(20)30368-9.
MLA-Zitierstil (9. Ausg.)Adams, David, et al. "Long-term Safety and Efficacy of Patisiran for Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: 12-month Results of an Open-label Extension Study." The Lancet, vol. 20, no. 1, 2021, https://doi.org/10.1016/S1474-4422(20)30368-9.